nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Connective tissue disorder—Fluocinolone Acetonide—psoriasis	0.00504	0.00504	CcSEcCtD
Cisatracurium Besylate—Erythema—Calcitriol—psoriasis	0.00503	0.00503	CcSEcCtD
Cisatracurium Besylate—Rash—Tazarotene—psoriasis	0.00482	0.00482	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Tazarotene—psoriasis	0.00481	0.00481	CcSEcCtD
Cisatracurium Besylate—Flushing—Acitretin—psoriasis	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Clobetasol propionate—psoriasis	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—psoriasis	0.00474	0.00474	CcSEcCtD
Cisatracurium Besylate—Urticaria—Beclomethasone—psoriasis	0.00468	0.00468	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Acitretin—psoriasis	0.00467	0.00467	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Mycophenolic acid—psoriasis	0.00465	0.00465	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Acitretin—psoriasis	0.00465	0.00465	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Fluocinolone Acetonide—psoriasis	0.00462	0.00462	CcSEcCtD
Cisatracurium Besylate—Pruritus—Clobetasol propionate—psoriasis	0.00458	0.00458	CcSEcCtD
Cisatracurium Besylate—Erythema—Acitretin—psoriasis	0.00448	0.00448	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methoxsalen—psoriasis	0.00448	0.00448	CcSEcCtD
Cisatracurium Besylate—Erythema—Fluocinolone Acetonide—psoriasis	0.00447	0.00447	CcSEcCtD
Cisatracurium Besylate—Wheezing—Triamcinolone—psoriasis	0.00443	0.00443	CcSEcCtD
Cisatracurium Besylate—Convulsion—Calcitriol—psoriasis	0.00436	0.00436	CcSEcCtD
Cisatracurium Besylate—Hypertension—Calcitriol—psoriasis	0.00435	0.00435	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Mycophenolic acid—psoriasis	0.00431	0.00431	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methoxsalen—psoriasis	0.00431	0.00431	CcSEcCtD
Cisatracurium Besylate—Injury—Cyclosporine—psoriasis	0.0043	0.0043	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fluocinonide—psoriasis	0.0043	0.0043	CcSEcCtD
Cisatracurium Besylate—Injury—Mycophenolate mofetil—psoriasis	0.0042	0.0042	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fluocinonide—psoriasis	0.00413	0.00413	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Calcitriol—psoriasis	0.00411	0.00411	CcSEcCtD
Cisatracurium Besylate—Angioedema—Acitretin—psoriasis	0.00409	0.00409	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Cyclosporine—psoriasis	0.00409	0.00409	CcSEcCtD
Cisatracurium Besylate—Rash—Clobetasol propionate—psoriasis	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Clobetasol propionate—psoriasis	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Calcitriol—psoriasis	0.00399	0.00399	CcSEcCtD
Cisatracurium Besylate—Injury—Prednisolone—psoriasis	0.00392	0.00392	CcSEcCtD
Cisatracurium Besylate—Injury—Hydrocortisone—psoriasis	0.00383	0.00383	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Prednisolone—psoriasis	0.00372	0.00372	CcSEcCtD
Cisatracurium Besylate—Rash—Beclomethasone—psoriasis	0.00372	0.00372	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Beclomethasone—psoriasis	0.00371	0.00371	CcSEcCtD
Cisatracurium Besylate—Rash—Fluocinonide—psoriasis	0.00368	0.00368	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fluocinonide—psoriasis	0.00368	0.00368	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Mycophenolate mofetil—psoriasis	0.00367	0.00367	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Hydroxyurea—psoriasis	0.00366	0.00366	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methoxsalen—psoriasis	0.00366	0.00366	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Hydrocortisone—psoriasis	0.00363	0.00363	CcSEcCtD
Cisatracurium Besylate—Injury—Triamcinolone—psoriasis	0.0036	0.0036	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.00357	0.00357	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Acitretin—psoriasis	0.00355	0.00355	CcSEcCtD
Cisatracurium Besylate—Erythema—Hydroxyurea—psoriasis	0.00352	0.00352	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Cyclosporine—psoriasis	0.00349	0.00349	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Mycophenolic acid—psoriasis	0.00344	0.00344	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Prednisolone—psoriasis	0.00342	0.00342	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Triamcinolone—psoriasis	0.00342	0.00342	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Mycophenolate mofetil—psoriasis	0.0034	0.0034	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methoxsalen—psoriasis	0.0034	0.0034	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Cyclosporine—psoriasis	0.00336	0.00336	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Hydrocortisone—psoriasis	0.00334	0.00334	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Mycophenolic acid—psoriasis	0.00332	0.00332	CcSEcCtD
Cisatracurium Besylate—Injury—Dexamethasone—psoriasis	0.00327	0.00327	CcSEcCtD
Cisatracurium Besylate—Injury—Betamethasone—psoriasis	0.00327	0.00327	CcSEcCtD
Cisatracurium Besylate—Urticaria—Calcitriol—psoriasis	0.00326	0.00326	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methoxsalen—psoriasis	0.00326	0.00326	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Prednisolone—psoriasis	0.00318	0.00318	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Triamcinolone—psoriasis	0.00315	0.00315	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Dexamethasone—psoriasis	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Betamethasone—psoriasis	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Hydrocortisone—psoriasis	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Mycophenolic acid—psoriasis	0.00307	0.00307	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Mycophenolic acid—psoriasis	0.00305	0.00305	CcSEcCtD
Cisatracurium Besylate—Convulsion—Hydroxyurea—psoriasis	0.00305	0.00305	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Calcitriol—psoriasis	0.00303	0.00303	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.00297	0.00297	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Triamcinolone—psoriasis	0.00292	0.00292	CcSEcCtD
Cisatracurium Besylate—Pruritus—Calcitriol—psoriasis	0.00291	0.00291	CcSEcCtD
Cisatracurium Besylate—Rash—Methoxsalen—psoriasis	0.00291	0.00291	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methoxsalen—psoriasis	0.0029	0.0029	CcSEcCtD
Cisatracurium Besylate—Urticaria—Acitretin—psoriasis	0.0029	0.0029	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Dexamethasone—psoriasis	0.00286	0.00286	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Betamethasone—psoriasis	0.00286	0.00286	CcSEcCtD
Cisatracurium Besylate—Injury—Prednisone—psoriasis	0.00285	0.00285	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Hydroxyurea—psoriasis	0.00281	0.00281	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Hydroxyurea—psoriasis	0.00279	0.00279	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Mycophenolate mofetil—psoriasis	0.00272	0.00272	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Acitretin—psoriasis	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Cyclosporine—psoriasis	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Dexamethasone—psoriasis	0.00265	0.00265	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Betamethasone—psoriasis	0.00265	0.00265	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.00262	0.00262	CcSEcCtD
Cisatracurium Besylate—Rash—Calcitriol—psoriasis	0.00259	0.00259	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Calcitriol—psoriasis	0.00259	0.00259	CcSEcCtD
Cisatracurium Besylate—Pruritus—Acitretin—psoriasis	0.00259	0.00259	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fluocinolone Acetonide—psoriasis	0.00258	0.00258	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Hydroxyurea—psoriasis	0.00256	0.00256	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mycophenolic acid—psoriasis	0.00255	0.00255	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mycophenolic acid—psoriasis	0.00254	0.00254	CcSEcCtD
Cisatracurium Besylate—Flushing—Cyclosporine—psoriasis	0.00254	0.00254	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Prednisolone—psoriasis	0.00254	0.00254	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00249	0.00249	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Prednisone—psoriasis	0.00249	0.00249	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Cyclosporine—psoriasis	0.00248	0.00248	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Hydrocortisone—psoriasis	0.00248	0.00248	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Cyclosporine—psoriasis	0.00247	0.00247	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Mycophenolate mofetil—psoriasis	0.00242	0.00242	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.00241	0.00241	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Hydrocortisone—psoriasis	0.00239	0.00239	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Mycophenolic acid—psoriasis	0.00236	0.00236	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mycophenolic acid—psoriasis	0.00235	0.00235	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mycophenolic acid—psoriasis	0.00233	0.00233	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Triamcinolone—psoriasis	0.00233	0.00233	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Prednisone—psoriasis	0.00231	0.00231	CcSEcCtD
Cisatracurium Besylate—Rash—Acitretin—psoriasis	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Acitretin—psoriasis	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Rash—Fluocinolone Acetonide—psoriasis	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fluocinolone Acetonide—psoriasis	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—psoriasis	0.00226	0.00226	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mycophenolic acid—psoriasis	0.00225	0.00225	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Hydrocortisone—psoriasis	0.0022	0.0022	CcSEcCtD
Cisatracurium Besylate—Angioedema—Cyclosporine—psoriasis	0.00218	0.00218	CcSEcCtD
Cisatracurium Besylate—Erythema—Prednisolone—psoriasis	0.00217	0.00217	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mycophenolic acid—psoriasis	0.00214	0.00214	CcSEcCtD
Cisatracurium Besylate—Angioedema—Mycophenolate mofetil—psoriasis	0.00212	0.00212	CcSEcCtD
Cisatracurium Besylate—Erythema—Hydrocortisone—psoriasis	0.00212	0.00212	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Betamethasone—psoriasis	0.00212	0.00212	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Dexamethasone—psoriasis	0.00212	0.00212	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Hydroxyurea—psoriasis	0.00211	0.00211	CcSEcCtD
Cisatracurium Besylate—Convulsion—Cyclosporine—psoriasis	0.00206	0.00206	CcSEcCtD
Cisatracurium Besylate—Hypertension—Cyclosporine—psoriasis	0.00206	0.00206	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.00201	0.00201	CcSEcCtD
Cisatracurium Besylate—Convulsion—Mycophenolate mofetil—psoriasis	0.00201	0.00201	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mycophenolate mofetil—psoriasis	0.00201	0.00201	CcSEcCtD
Cisatracurium Besylate—Erythema—Triamcinolone—psoriasis	0.00199	0.00199	CcSEcCtD
Cisatracurium Besylate—Angioedema—Prednisolone—psoriasis	0.00198	0.00198	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.00197	0.00197	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Cyclosporine—psoriasis	0.00194	0.00194	CcSEcCtD
Cisatracurium Besylate—Angioedema—Hydrocortisone—psoriasis	0.00193	0.00193	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Cyclosporine—psoriasis	0.00191	0.00191	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.0019	0.0019	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Cyclosporine—psoriasis	0.00189	0.00189	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Dexamethasone—psoriasis	0.00189	0.00189	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Betamethasone—psoriasis	0.00189	0.00189	CcSEcCtD
Cisatracurium Besylate—Convulsion—Prednisolone—psoriasis	0.00188	0.00188	CcSEcCtD
Cisatracurium Besylate—Hypertension—Prednisolone—psoriasis	0.00187	0.00187	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.00186	0.00186	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Mycophenolate mofetil—psoriasis	0.00185	0.00185	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Mycophenolate mofetil—psoriasis	0.00184	0.00184	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Prednisone—psoriasis	0.00184	0.00184	CcSEcCtD
Cisatracurium Besylate—Convulsion—Hydrocortisone—psoriasis	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Hypertension—Hydrocortisone—psoriasis	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Angioedema—Triamcinolone—psoriasis	0.00182	0.00182	CcSEcCtD
Cisatracurium Besylate—Rash—Hydroxyurea—psoriasis	0.00181	0.00181	CcSEcCtD
Cisatracurium Besylate—Erythema—Dexamethasone—psoriasis	0.00181	0.00181	CcSEcCtD
Cisatracurium Besylate—Erythema—Betamethasone—psoriasis	0.00181	0.00181	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Hydroxyurea—psoriasis	0.00181	0.00181	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.00179	0.00179	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Prednisone—psoriasis	0.00178	0.00178	CcSEcCtD
Cisatracurium Besylate—Hypotension—Mycophenolate mofetil—psoriasis	0.00177	0.00177	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Prednisolone—psoriasis	0.00177	0.00177	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Cyclosporine—psoriasis	0.00173	0.00173	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Hydrocortisone—psoriasis	0.00173	0.00173	CcSEcCtD
Cisatracurium Besylate—Convulsion—Triamcinolone—psoriasis	0.00173	0.00173	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Prednisolone—psoriasis	0.00173	0.00173	CcSEcCtD
Cisatracurium Besylate—Hypertension—Triamcinolone—psoriasis	0.00172	0.00172	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mycophenolic acid—psoriasis	0.0017	0.0017	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Hydrocortisone—psoriasis	0.00169	0.00169	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00169	0.00169	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Hydrocortisone—psoriasis	0.00169	0.00169	CcSEcCtD
Cisatracurium Besylate—Flushing—Prednisone—psoriasis	0.00168	0.00168	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Hydrocortisone—psoriasis	0.00168	0.00168	CcSEcCtD
Cisatracurium Besylate—Angioedema—Dexamethasone—psoriasis	0.00165	0.00165	CcSEcCtD
Cisatracurium Besylate—Angioedema—Betamethasone—psoriasis	0.00165	0.00165	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Prednisone—psoriasis	0.00164	0.00164	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Prednisone—psoriasis	0.00163	0.00163	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Triamcinolone—psoriasis	0.00163	0.00163	CcSEcCtD
Cisatracurium Besylate—Hypotension—Hydrocortisone—psoriasis	0.00161	0.00161	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Triamcinolone—psoriasis	0.00159	0.00159	CcSEcCtD
Cisatracurium Besylate—Erythema—Prednisone—psoriasis	0.00158	0.00158	CcSEcCtD
Cisatracurium Besylate—Convulsion—Betamethasone—psoriasis	0.00157	0.00157	CcSEcCtD
Cisatracurium Besylate—Convulsion—Dexamethasone—psoriasis	0.00157	0.00157	CcSEcCtD
Cisatracurium Besylate—Hypertension—Dexamethasone—psoriasis	0.00156	0.00156	CcSEcCtD
Cisatracurium Besylate—Hypertension—Betamethasone—psoriasis	0.00156	0.00156	CcSEcCtD
Cisatracurium Besylate—Urticaria—Cyclosporine—psoriasis	0.00154	0.00154	CcSEcCtD
Cisatracurium Besylate—Rash—Mycophenolic acid—psoriasis	0.00152	0.00152	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mycophenolic acid—psoriasis	0.00151	0.00151	CcSEcCtD
Cisatracurium Besylate—Urticaria—Mycophenolate mofetil—psoriasis	0.00151	0.00151	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Betamethasone—psoriasis	0.00148	0.00148	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Dexamethasone—psoriasis	0.00148	0.00148	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Triamcinolone—psoriasis	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Betamethasone—psoriasis	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Dexamethasone—psoriasis	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Betamethasone—psoriasis	0.00144	0.00144	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Dexamethasone—psoriasis	0.00144	0.00144	CcSEcCtD
Cisatracurium Besylate—Angioedema—Prednisone—psoriasis	0.00144	0.00144	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Cyclosporine—psoriasis	0.00143	0.00143	CcSEcCtD
Cisatracurium Besylate—Urticaria—Prednisolone—psoriasis	0.00141	0.00141	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.0014	0.0014	CcSEcCtD
Cisatracurium Besylate—Hypotension—Dexamethasone—psoriasis	0.00138	0.00138	CcSEcCtD
Cisatracurium Besylate—Hypotension—Betamethasone—psoriasis	0.00138	0.00138	CcSEcCtD
Cisatracurium Besylate—Pruritus—Cyclosporine—psoriasis	0.00138	0.00138	CcSEcCtD
Cisatracurium Besylate—Urticaria—Hydrocortisone—psoriasis	0.00137	0.00137	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—psoriasis	0.00137	0.00137	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—psoriasis	0.00137	0.00137	CcSEcCtD
Cisatracurium Besylate—Convulsion—Prednisone—psoriasis	0.00136	0.00136	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—psoriasis	0.00136	0.00136	CcSEcCtD
Cisatracurium Besylate—Hypertension—Prednisone—psoriasis	0.00136	0.00136	CcSEcCtD
Cisatracurium Besylate—Pruritus—Mycophenolate mofetil—psoriasis	0.00134	0.00134	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00133	0.00133	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—psoriasis	0.00132	0.00132	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Prednisolone—psoriasis	0.0013	0.0013	CcSEcCtD
Cisatracurium Besylate—Urticaria—Triamcinolone—psoriasis	0.00129	0.00129	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Prednisone—psoriasis	0.00129	0.00129	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Hydrocortisone—psoriasis	0.00127	0.00127	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Prednisone—psoriasis	0.00126	0.00126	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Prednisone—psoriasis	0.00125	0.00125	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Prednisone—psoriasis	0.00125	0.00125	CcSEcCtD
Cisatracurium Besylate—Rash—Cyclosporine—psoriasis	0.00123	0.00123	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Cyclosporine—psoriasis	0.00122	0.00122	CcSEcCtD
Cisatracurium Besylate—Pruritus—Hydrocortisone—psoriasis	0.00122	0.00122	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Triamcinolone—psoriasis	0.0012	0.0012	CcSEcCtD
Cisatracurium Besylate—Rash—Mycophenolate mofetil—psoriasis	0.0012	0.0012	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mycophenolate mofetil—psoriasis	0.00119	0.00119	CcSEcCtD
Cisatracurium Besylate—Urticaria—Betamethasone—psoriasis	0.00117	0.00117	CcSEcCtD
Cisatracurium Besylate—Urticaria—Dexamethasone—psoriasis	0.00117	0.00117	CcSEcCtD
Cisatracurium Besylate—Pruritus—Triamcinolone—psoriasis	0.00115	0.00115	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—psoriasis	0.00114	0.00114	CcSEcCtD
Cisatracurium Besylate—Rash—Prednisolone—psoriasis	0.00112	0.00112	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Prednisolone—psoriasis	0.00111	0.00111	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00111	0.00111	CcSEcCtD
Cisatracurium Besylate—Rash—Hydrocortisone—psoriasis	0.00109	0.00109	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Hydrocortisone—psoriasis	0.00109	0.00109	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—psoriasis	0.00107	0.00107	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—psoriasis	0.00105	0.00105	CcSEcCtD
Cisatracurium Besylate—Pruritus—Dexamethasone—psoriasis	0.00104	0.00104	CcSEcCtD
Cisatracurium Besylate—Pruritus—Betamethasone—psoriasis	0.00104	0.00104	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—psoriasis	0.00104	0.00104	CcSEcCtD
Cisatracurium Besylate—Rash—Triamcinolone—psoriasis	0.00103	0.00103	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Triamcinolone—psoriasis	0.00102	0.00102	CcSEcCtD
Cisatracurium Besylate—Urticaria—Prednisone—psoriasis	0.00102	0.00102	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—psoriasis	0.001	0.001	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—psoriasis	0.000958	0.000958	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Prednisone—psoriasis	0.000947	0.000947	CcSEcCtD
Cisatracurium Besylate—Rash—Betamethasone—psoriasis	0.000931	0.000931	CcSEcCtD
Cisatracurium Besylate—Rash—Dexamethasone—psoriasis	0.000931	0.000931	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Betamethasone—psoriasis	0.00093	0.00093	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Dexamethasone—psoriasis	0.00093	0.00093	CcSEcCtD
Cisatracurium Besylate—Pruritus—Prednisone—psoriasis	0.00091	0.00091	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—psoriasis	0.000854	0.000854	CcSEcCtD
Cisatracurium Besylate—Rash—Prednisone—psoriasis	0.000811	0.000811	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Prednisone—psoriasis	0.00081	0.00081	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—psoriasis	0.000792	0.000792	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—psoriasis	0.00076	0.00076	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—psoriasis	0.000678	0.000678	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—psoriasis	0.000677	0.000677	CcSEcCtD
